Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment

Core Insights - Bioxytran, Inc. is making significant progress in the development of its antiviral drug ProLectin-M, which is currently under an active Investigational New Drug (IND) application with the FDA [1] - ProLectin-M targets the galectin fold on spike proteins of various viruses, including SARS-CoV-2, influenza, and RSV, demonstrating high efficacy in clinical trials [2] - The drug's development aligns with a shift in U.S. health policy, creating a unique opportunity for Bioxytran as resources are redirected away from mRNA vaccines [3] Company Overview - Bioxytran is focused on developing linear complex carbohydrate-based therapeutics to address unmet medical needs in virology, cancer metastasis, and oxygen transport [5] - The company is advancing multiple programs, including ProLectin-M and a stroke treatment program utilizing an FDA-approved device [5] Research and Development - ProLectin-M has shown a complete response in clinical trials, with negative PCR tests in all subjects by day 7 and an 88% response rate by day 3 [2] - The drug's mechanism involves blocking galectins to prevent viral attachment to host cells, with ongoing research into its efficacy against other viruses like Epstein-Barr Virus [4]